Healthequity, Inc.
$8.59B- Market cap
- $7.95B
- Debt
- +$957.38M
- Cash
- −$318.93M
Capital structure 89% equity / 11% debt · EV / Revenue 6.54x · EV / EBITDA 17.73x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt cap
Decision snapshot: HQY stock price near parity vs NUE $96.09 current versus $85.42 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NUE's multiple
Implied fair value · at HQY's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Premium justified
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HQY FY 2026 (ended Jan 31, 2026) · NUE FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 89% equity / 11% debt · EV / Revenue 6.54x · EV / EBITDA 17.73x
Capital structure 89% equity / 11% debt · EV / Revenue 1.95x · EV / EBITDA 16.19x
NUE carries the larger enterprise value at $63.52B against $8.59B; NUE trades on the lower EV / Revenue multiple (1.95x vs 6.54x); NUE on the lower EV / EBITDA (16.19x vs 17.73x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HEALTHEQUITY, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
NUCOR CORP · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.45x
0.33x
Net debt / EBITDA
Leverage against operating earnings
1.32x
1.09x
Cash and equivalents
Liquid reserves on the balance sheet
$318.93M
$2.70B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$957.38M
$6.98B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HQY can sustain its 9.5% revenue growth and 41.3% EBITDA margin without multiple compression, then hold or accumulate on weakness because the operating profile is stronger than NUE’s, but the current price already appears ahead of the P/E-based implied value.
HQY trades at a premium multiple set versus NUE on most valuation measures, with P/E of 42.0x versus 36.5x and P/S of 6.6x versus 1.9x. The model-implied price of $89.76 is 13.1% below the current price of $103.34, indicating the market is already pricing in stronger fundamentals than the simple P/E framework supports.
Supporting Metrics